JPMorgan Chase & Co. Buys 2,062,563 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

JPMorgan Chase & Co. increased its holdings in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) by 475.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,495,922 shares of the company's stock after acquiring an additional 2,062,563 shares during the quarter. JPMorgan Chase & Co. owned about 2.76% of Caribou Biosciences worth $3,969,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. US Bancorp DE grew its position in shares of Caribou Biosciences by 3,524.2% in the fourth quarter. US Bancorp DE now owns 27,218 shares of the company's stock valued at $43,000 after purchasing an additional 26,467 shares during the last quarter. Thrive Wealth Management LLC acquired a new position in Caribou Biosciences in the 4th quarter valued at $51,000. Intech Investment Management LLC increased its position in Caribou Biosciences by 69.4% during the 4th quarter. Intech Investment Management LLC now owns 37,478 shares of the company's stock worth $60,000 after buying an additional 15,352 shares during the period. Sei Investments Co. acquired a new stake in shares of Caribou Biosciences during the fourth quarter worth $102,000. Finally, Barclays PLC boosted its position in shares of Caribou Biosciences by 122.4% in the third quarter. Barclays PLC now owns 129,839 shares of the company's stock valued at $255,000 after acquiring an additional 71,463 shares during the period. Institutional investors own 77.51% of the company's stock.

Caribou Biosciences Stock Up 0.8 %

Shares of NASDAQ:CRBU traded up $0.01 during midday trading on Wednesday, hitting $0.84. The stock had a trading volume of 949,656 shares, compared to its average volume of 1,558,585. The company's 50-day moving average price is $1.01 and its 200-day moving average price is $1.56. Caribou Biosciences, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $4.21. The company has a market capitalization of $78.34 million, a P/E ratio of -0.51 and a beta of 2.36.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.08 million during the quarter, compared to the consensus estimate of $2.11 million. Research analysts expect that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on CRBU. HC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of Caribou Biosciences in a research report on Wednesday, March 19th. Bank of America dropped their price target on shares of Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Caribou Biosciences currently has a consensus rating of "Buy" and an average target price of $10.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.